View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 25, 2017

M&As this week: Bioverativ Therapeutics, Horizon Pharma

Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Based in the US, the target company is focused on developing treatments for rare diseases.

The purchase consideration for the acquisition is fixed at $825m, which includes an upfront payment of $400m and the remaining contingent on the achievement of certain milestones related to development, regulatory and sales.

True North’s drug candidate TNT009 aims to treat a rare blood disorder known as CAD and will strengthen Boverativ’s portfolio as a result of the acquisition.

"Irish biopharmaceutical company Horizon Pharma has reached an agreement to sell one of its European subsidiaries to Chiesi Farmaceutici, a pharmaceutical company based in Italy."

Also based in the US, Bioverativ is a biopharmaceutical company focused on developing therapies for haemophilia and other rare blood disorders.

Irish biopharmaceutical company Horizon Pharma has reached an agreement to sell one of its European subsidiaries to Chiesi Farmaceutici, a pharmaceutical company based in Italy.

The subsidiary owns the marketing rights to PROCYSBI delayed-release capsules and QUINSAIR, a levofloxacin inhalation solution, in Europe, the Middle East and Africa (EMEA).

Chiesi Farmaceutici believes the transaction will help further strengthen its rare disease offering in the EMEA regions.

The purchase consideration for the transaction includes $70m in upfront payment and additional potential payments based on the achievement of sales-based milestones.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena